Press Releases

BOSTON, MA – March 3, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that it has entered into a definitive agreement to sell up to approximately 34 million shares of common stock and warrants to purchase up to approximately 34 million shares of… Read More

Presentation to be Webcast on March 3, 2015 at 10:40 a.m. ET BOSTON, MA – February 26, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that its Chief Executive Officer, Alan Milinazzo, will present at the Cowen and Company 35th Annual Healthcare Conference… Read More

The New CGuardTM RX Rapid Exchange System Receives CE Mark Approval Six-Month Ultrasound Analysis Confirms Widely Patent Internal and External Carotid Arteries When Compared to Conventional Carotid Stents   BOSTON, MA – January 27, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced that… Read More

BOSTON, MA – January 21, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced the receipt of a notice indicating that InspireMD does not meet certain of the NYSE MKT LLC’s (the “NYSE MKT”) continued listing standards as set forth in Part 10 of… Read More

CGuardTM All Comer Data Continues to Show Excellent Clinical Benefits of the MicroNet™TM Covered Technology Six-Month Ultrasound Analysis is Indicative of Patent Carotid Arteries Without Restenosis Concern When Compared to Conventional Carotid Stents   BOSTON, MA – January 13, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection… Read More

Near-term Focus On Carotid and DES Products, Streamlined Operations   BOSTON, MA – January 5, 2015 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced its revenue and cash position for the 2014 fourth quarter, ended December 31. Total revenues were approximately $900,000, which represented… Read More

MASTER I and MASTER II Pooled Data Show Statistically Significant Mortality Benefit  CARENET 30 Day DW-MRI Data Demonstrates Significant Reduction in New Ischemic Ipsilateral Lesions BOSTON, MA – December 15, 2014 — InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic protection systems (“EPS”), today announced results from two important clinical trials…. Read More

Master II 30 day data to be presented December 15th at the ICI Meeting 2014, Tel-Aviv  Announced first pre-clinical implant with partner DES platform BOSTON, MA – November 12, 2014 – InspireMD, Inc.(NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems (“EPS”), today announced its financial and operating results for… Read More

BOSTON, MA – November 7, 2014 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in stent Embolic Protection Systems (EPS), today announced the closing of its registered direct offering of approximately 6.2 million shares of common stock and warrants to purchase up to approximately 3.1 million shares of common stock at a price of… Read More

BOSTON, MA – November 5, 2014 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in stent embolic protection systems, announced today that it will release its financial results for the third quarter ended September 30, 2014 on Wednesday, November 12th.   The Company will host a conference call at 4:30 p.m…. Read More